Welcome to the INA-RESPOND public website.
Current and expanding infectious disease profile in Indonesia warrants a sense of urgency and mandates that research be a priority to guide the management and prevention of disease to reduce morbidity and mortality. The purpose of Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) is to bring together clinical and academic medical institutions to develop a robust collaborative infectious disease research network.
WEBINAR SERIES ONE YEAR LIVING WITH SARS-COV-2: PROGRESS ON PREVENTION AND TREATMENT The First Webinar series, “Updates on COVID-19 Vaccine”, was held on Saturday, April 10, 2021, at 08.00-12.00 WIB. This webinar is supported by INA-RESPOND and partners and is free of charge for all participants. Participants will receive IDI SKP and an electronic certificate.
The Identification of First COVID-19 Cluster in Indonesia Vivi Setiawaty,1 Herman Kosasih,2,* Yan Mardian,2 Emita Ajis,3 Endang Burni Prasetyowati,3 Siswanto,1 Muhammad Karyana,1,2 and SARS-CoV-2 Reference Laboratory, Ministry of Health, Indonesia Abstract. We describe the first 11 detected COVID-19 cases in Indonesia, resulting from a local transmission occurring in a club and a restaurant. The virus was detected until an average of 21.3
“Leptospirosis in Indonesia: Diagnostic challenges associated with atypical manifestations and limited laboratory capacity”. Muhammad Hussein Gasem, Usman Hadi, Bachti Alisjahbana, Emiliana Tjitra, Muhammad Karyana, MMDEAH Hapsari, Endang Sri Lestari, Herman Kosasih, Abu Tholib Aman, Dewi Lokida, Gustiani Salim, Kanti Laras, Nurhayati Lukman, Ketut Tuti Parwati Merati, Mansyur Arif, Pratiwi Sudarmono, Vivi Lisdawati, Chuen-Yen Lau, Aaron
We have gone through a lot in 2019. The year has been proven as exciting and challenging as ever, but with perseverance and solid team work, we have managed to come through victorious! Check out our network’s latest accomplishment. 2019 INA-RESPOND accomplishments
To collect standardized baseline and longitudinal data describing the course of HIV disease in antiretroviral-naive and treatment-experienced individuals to inform policy.
Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests, Biomarkers and Standard of Care Procedures) for the Etiology Diagnosis of Pneumonia in Paediatric Patients to Improve Clinical Management in Indonesia
To identify COVID-19 and other respiratory infectious disease cases from hospitalized suspected COVID-19 patients.
to compare the virological efficacy of the three regimens in the intention to treat (ITT) population. Virological efficacy is defined as the proportion of participants with plasma HIV RNA (pVL) <50 copies/mL at 48 weeks.
Among participants testing positive for SARS-CoV-2: Estimate the rate of hospitalization or death during the 28 day follow-up period. Identify risk factors for hospitalization or death.
The primary endpoint of this trial in hospitalized patients is an ordinal outcome based on the patient’s clinical status on Day 7. It includes seven mutually exclusive categories capturing the range of organ dysfunction that may be associated with the progression of COVID-19, such as respiratory dysfunction and coagulation-related complications.
To identify the etiology of acute febrile illness cases and evaluate clinical manifestations and outcomes.
To determine the causes of community-acquired sepsis and severe sepsis in adults and pediatrics across Southeast Asia.
To estimate the proportion of MDR TB amongst treatment naïve new treatment naïve and previously treated cases.
